No reason to change WHO guidelines on cleansing the umbilical cord
20 years ago, neonatal survival was not on the global health agenda. In many low-income settings, infants died without recognition, causing untold grief. However, the past two decades have seen steady improvements in neonatal survival on a background of sustained advocacy, a culture of community-based trials, and improvements in quantity and quality of health care, health behaviour, and demand for services. Nevertheless, an annual 2·7 million newborn babies still do not survive their fi rst month of life. tested umbilical cord cleansing with antiseptic solution. Supporting evidence to date has come from randomised controlled trials in south Asia, which suggested that cleansing with chlorhexidine solution could reduce both periumbilical infl ammation (omphalitis) and neonatal mortality.
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In a previous Comment 7 we suggested that the putative eff ects might diminish at scale, that it would be good for families to do the cord cleansing themselves, and that evidence from high-mortality populations in Africa would be helpful. In the interim, a meta-analysis 8 estimated the combined risk ratio (RR) for neonatal mortality at 0·77 (95% CI 0·63-0·94).
Katherine Semrau and colleagues 2 did a clusterrandomised controlled trial in Southern Province, Zambia. Fieldworkers visited women antenatally within 24 h of delivery, and repeatedly during the newborns' fi rst month of life. Families in the intervention group were given 4% chlorhexidine solution to apply 10 mL, using eyedropper bottles, once per day until cord separation, whereas families in the control group were encouraged to maintain dry cord care. Semrau and colleagues 2 reported no diff erence between allocation groups in the primary outcome of neonatal mortality rate (deaths [in the fi rst 28 days post-partum] per 1000 livebirths; RR 1·12, 95% CI 0·88-1·44) or the secondary outcome of occurrence of omphalitis (diagnosed by erythema or purulent discharge; 0·73, 0·47-1·13).
Sunil Sazawal and colleagues 3 did a communitybased, individually-randomised controlled trial in Pemba Island, Tanzania. Maternal-child health workers visited on the day of delivery and days 1, 4, 10, and 28; showed families how to care for the cord; and gave them 4% chlorhexidine solution to apply once per day, using 10 mL dropper bottles, until cord separation. The trial 3 began with three comparison groups-dry cord care, chlorhexidine treatment group, or control group using a placebo solution-but the control group was dropped in the second phase of the study. Sazawal and colleagues 3 reported no diff erence between allocation groups in On a spectrum of effi cacy, the trials were pitched toward real-world conditions. The interventions were delivered by project staff , but mothers were encouraged to apply the treatment themselves. Whether or not they did so-and it seems likely that they did (98% compliance was reported in the Zambia study 2 )-it was an intention-to-treat approach. Two important issues aff ect our interpretation of these fi ndings. First, many women chose institutional delivery (53% of deliveries were at hospitals in Sazawal and colleagues' trial, and 64% in Semrau and colleagues' trial 2 ). The latest WHO guidelines 9 recommend application of chlorhexidine to the umbilical cord stump for the fi rst week after birth, for infants born at home in environments with high neonatal mortality rates (>30 deaths per 1000 livebirths). Dry cord care is recommended after institutional births or home births in settings with lower neonatal mortality rates. 9 Chlorhexidine might be considered as a replacement for harmful applications to the cord stump, 9 but Cochrane reviews, a meta-analysis, 8 and these two new trials 2, 3 have not supported an eff ect after hospital births. 10, 11 Second, the neonatal mortality rates were lower than expected. The sample size for the Zambian study 2 was developed on the assumption that the neonatal mortality rate in the control group would be 29·0 deaths per 1000 livebirths. However, the observed rate was 14·4 deaths per 1000 livebirths. The Tanzanian study 3 assumed a control group neonatal mortality rate of 31 deaths per 1000 livebirths. The observed neonatal mortality rate was 11·7 deaths per 1000 livebirths. Both trials increased their sample sizes during implementation, yet confi dence intervals around estimates of eff ects on neonatal mortality rates were nevertheless substantial. To address the issue of underpowering, the research groups combined their estimates in a random-eff ects meta-analysis, resulting in a relative risk estimate of 0·99 (95% CI 0·80-1·23) for neonatal mortality by day 28.
The three major drivers of newborn mortality are infection, preterm birth, and presumed intrapartum-related compromise. The implicit assumption is that antiseptic cleansing will prevent microbial invasion and reduce deaths from infection. However, as neonatal mortality rates decrease, the proportion of deaths explained by infection reduces in relation to the other two causes. What this means is that the yield in terms of reduction in all-cause mortality as a result of cord antisepsis is likely to be lower in settings with low neonatal mortality rates. To test our assumption, we used the published fi ndings of the fi ve trials [2] [3] [4] [5] [6] as a basis for conservative metaregression. The fi gure shows the reduction in mortality associated with varying proportions of home delivery and neonatal mortality rates. Although not signifi cant, the impression is that higher neonatal mortality rates (p=0·109) and a higher proportion of home deliveries (p=0·138) were associated with larger eff ects of cord cleansing on neonatal mortality rates.
Along with the individual trial fi ndings, the fi gure is consonant with the current WHO guidelines 9 for cord care, to which we recommend no change. Cord cleanliness is part of the suite of hard-won improvements that accompany the increases in survival being seen worldwide. In settings in which neonatal mortality rates remain high, we recommend the kinds of programme that have been associated with reductions in all-cause mortality. These include improvements in institutional quality of care and eff orts to improve community-based practices, both central to the 2014 Every Newborn Action Plan.
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